Table of contents
- Trial overview
- Who can join the study
- What is being tested
- Study phase and size
- What researchers measure
Trial overview
The listed study is an interventional clinical trial, which means researchers give a treatment and then watch what happens.[1] It is studying Azd3470 in people with advanced/metastatic solid tumors that are MTAP deficient.[1] The trial is authorised and plans to include 234 participants.[1]
Who can join the study
This study is for participants with advanced or metastatic solid tumors that are MTAP deficient.[1] In simple terms, this means the cancer has grown beyond its original site, and the tumor has a specific missing feature called MTAP.[1]
The trial data does not give more detailed eligibility rules, so the main group described is people with this cancer type and tumor feature.[1]
What is being tested
The brief summary says the study aims to assess the safety and tolerability of Azd3470 and to find the recommended phase 2 dose (RP2D).[1] RP2D means the dose that may be chosen for later studies after early testing.[1]
Azd3470 is being tested as monotherapy, meaning by itself, and also in combination with anti-cancer agents.[1] This helps researchers compare how the treatment works alone and together with other cancer medicines.[1]
Study phase and size
The trial is in Phase 1.[1] Phase 1 studies usually look first at safety, side effects, and dose selection rather than proving benefit.[1]
The planned enrollment is 234 people.[1] That number gives an idea of how many participants the researchers hope to include in the study.[1]
What researchers measure
The main outcomes are adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLT).[1] These are ways to track unwanted medical problems during the study, from common side effects to more serious problems that can limit treatment.[1]
Researchers will count these events by system organ class and preferred term, which is a standard way to group and name medical problems in a clinical trial.[1] This helps the team understand which side effects happen and how often they occur.[1]
Why this study matters
This trial is an early step in learning whether Azd3470 can be studied further in people with a specific type of advanced cancer.[1] The main goal is not yet to prove long-term benefit, but to gather early information that can guide later research.[1]
Because the study includes both single-treatment and combination-treatment parts, it may help researchers understand whether Azd3470 should move forward alone, with other anti-cancer agents, or both.[1]
